Syntec Optics (Nasdaq: OPTX) Enabling Optics for Blindness
ROCHESTER, NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) — Syntec Optics, a scientific technical instruments, aerospace and defense optics provider […]
Synaptics Announces Chief Financial Officer Transition
SAN JOSE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) today announced the resignation of its Chief […]
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
– Reported OGSIVEO™ (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on […]
TSX News -
Hut 8 Commences Construction of New Digital Asset Mining Site in Culberson County, Announces New Treasury Strategy
63 MW site, planned to be energized in Q2, will be Hut 8’s newest North American mining operation Site expected […]
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First […]
Lavras Gold Corp. Chosen to Exhibit at PDAC Core Shack, March 3-4, Booth #3101A & Investors Exchange Booth 2831
TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — Lavras Gold Corp. (TSX-V:LGC, OTCQX:LGCFF) (“Lavras” or the “Company”) is pleased to have […]
Hesai Group to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 11, 2024
SHANGHAI, China, Feb. 27, 2024 (GLOBE NEWSWIRE) — Hesai Group (“Hesai,” “Hesai Technology” or the “Company”) (NASDAQ: HSAI), the global […]
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
Launched XDEMVY®(lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 […]
Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results
Achieved All 2023 Operating and Financial Guidance Metrics Implemented Providers +19.4% compared to Year-End 2022 Introduces Full-Year 2024 Guidance Proactive […]
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused […]
